Basilea Pharmaceutica Ltd. Logo
 
Home
 
 
Search
 
Stock Information
Featured Bugs
Aspergillus fumigatus
 more...
 
Welcome to Basilea
 
 
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX:BSLN). Basilea's integrated research and development operations are currently focused on new antibacterial, antifungal and oncology agents to fight drug resistance and on the development of dermatology drugs. Basilea's products are targeted to satisfy high medical and patient needs in the hospital and specialty care setting.
 
Basilea owns a broad and balanced late-stage product portfolio including novel treatments for resistant bacterial infections, systemic fungal infections and severe skin diseases. The company's diversified portfolio includes two commercialized drugs (alitretinoin, ceftobiprole), one investigational drug in phase III (isavuconazole) as well as innovative earlier-stage programs. Basilea has entered into a license, co-development and co-promotion agreement with Astellas Pharma Inc. for isavuconazole for the treatment of life-threatening invasive fungal infections on a worldwide basis, including an option for Japan. Toctino® (alitretinoin) is marketed in Denmark, France, Germany, Switzerland and the United Kingdom. It is approved in six additional European countries as well as in Canada and has been recommended for approval in 15 European countries. Furthermore, a phase III clinical trial on alitretinoin for the treatment of severe chronic hand eczema is ongoing in the U.S. Ceftobiprole is marketed in Canada under the brand name ZEFTERA™ and in Switzerland under Zevtera™.

Basilea has a fully integrated R&D organization and has set up commercial organizations in Canada, France, Germany, the Nordics, Switzerland and the United Kingdom, while it is building sales and marketing organizations in other countries to commercialize alitretinoin, subject to approval.

 
News
 
 
Language
 
Thursday, March 11. 2010
 
Basel, Switzerland, March 11, 2010 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announces that the Applicant Janssen-Cilag International NV (Janssen-Cilag), a Johnson & Johnson company, has submitted a request for re-examination of the negative opinion by the European Committee for Medicinal Products for Human Use (CHMP) on the Marketing Authorization Application (MAA) for ceftobiprole for the treatment of complicated skin and soft tissue infections (cSSTI).
 
more...
 
Wednesday, February 24. 2010
 
Basel, Switzerland, February 24, 2010 - Basilea (SIX:BSLN) announced today that Basilea Pharmaceutica International Ltd. has entered into a license, co-development and co-promotion agreement with Astellas Pharma Inc. (TSE:4503) for Basilea's azole antifungal agent isavuconazole in phase III clinical development for the treatment of life-threatening invasive fungal infections on a worldwide basis, including an option for Japan.
 
more...
 
Friday, February 19. 2010
 
Basel, Switzerland, February 19, 2010 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announces that after the negative decision by the CHMP today, Cilag GmbH International, a Johnson & Johnson company, has given notice that it will return global rights of ceftobiprole to Basilea.
 
more...
 
Friday, February 19. 2010
 
Basel, Switzerland, February 19, 2010 -  Basilea Pharmaceutica Ltd. (SIX:BSLN) announces that the European Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on the Marketing Authorization Application (MAA) for ceftobiprole for the treatment of complicated skin and soft tissue infections (cSSTI).
 
more...
 
Info
 
 
 

IDSA
Infectious Diseases
Society of America
 
National Eczema Association
for Science and Education
 
Doctorfungus